Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 7 | 1 |
| List of Figures | 7 | 1 |
| ADHD Therapeutics Market to 2018 Introduction | 8 | 9 |
| Etiology and Pathophysiology | 8 | 1 |
| Genetic Influences | 8 | 1 |
| Environmental Influences | 8 | 1 |
| Pathophysiology | 8 | 1 |
| Epidemiology | 9 | 1 |
| Child/Adult Subpopulations | 9 | 1 |
| Male/Female | 9 | 1 |
| Diagnosis | 9 | 1 |
| DSM-IV Criteria for ADHD | 9 | 2 |
| DSM-V Revision | 11 | 1 |
| ICD-10 Criteria for Hyperkinetic Disorder | 12 | 1 |
| Diagnostic Rating Scales | 13 | 1 |
| Issues with Diagnosis | 13 | 1 |
| Co-Morbid Disorders | 14 | 1 |
| Treatment and Management Options | 15 | 1 |
| Pharmacologic Treatment | 15 | 1 |
| Drivers and Barriers for ADHD Therapeutics Market | 15 | 1 |
| Drivers | 15 | 1 |
| High Prevalence of ADHD | 15 | 1 |
| Need for Effective Non-Stimulant Therapies | 15 | 1 |
| Barriers | 16 | 1 |
| Increasingly Competitive Market | 16 | 1 |
| Social Factors | 16 | 1 |
| High Level of Co-Morbidity | 16 | 1 |
| ADHD Therapeutics: Market Characterization by Geography | 17 | 17 |
| All Major Markets | 17 | 1 |
| Market Size All Major Markets | 17 | 1 |
| Market Forecast All Major Markets | 18 | 1 |
| Annual Cost of Therapy Average of All Major Markets | 19 | 1 |
| The US | 20 | 1 |
| Market Size The US | 20 | 1 |
| Market Forecast - The US | 21 | 1 |
| Annual Cost of Therapy The US | 21 | 1 |
| Top 5 Countries of Europe | 22 | 1 |
| Market Size France | 22 | 1 |
| Market Forecast France | 22 | 1 |
| Annual Cost of Therapy France | 23 | 1 |
| Market Size Germany | 24 | 1 |
| Market Forecast Germany | 24 | 1 |
| Annual Cost of Therapy Germany | 25 | 1 |
| Market Size Italy | 26 | 1 |
| Market Forecast Italy | 26 | 1 |
| Annual Cost of Therapy Italy | 27 | 1 |
| Market Size Spain | 28 | 1 |
| Market Forecast Spain | 28 | 1 |
| Annual Cost of Therapy Spain | 29 | 1 |
| Market Size The UK | 30 | 1 |
| Market Forecast The UK | 30 | 1 |
| Average Annual Cost of Therapy The UK | 31 | 1 |
| Japan | 32 | 1 |
| Market Size Japan | 32 | 1 |
| Market Forecast Japan | 33 | 1 |
| Annual Cost of Therapy Japan | 33 | 1 |
| ADHD Therapeutics Market to 2018 Competitive Landscape | 34 | 7 |
| Overview of Major Marketed Products in the ADHD market | 34 | 1 |
| Adderall XR (mixed amphetamine salt) | 34 | 1 |
| Overview | 34 | 1 |
| Efficacy | 34 | 1 |
| Safety | 35 | 1 |
| Daytrana (methylphenidate transdermal patch) | 35 | 1 |
| Overview | 35 | 1 |
| Efficacy | 35 | 1 |
| Safety | 35 | 1 |
| Concerta (methylphenidate hydrochloride) | 36 | 1 |
| Overview | 36 | 1 |
| Efficacy | 36 | 1 |
| Safety | 36 | 1 |
| Intuniv (guanfacine) | 36 | 1 |
| Overview | 36 | 1 |
| Efficacy | 36 | 1 |
| Safety | 37 | 1 |
| Strattera (atomoxetine hydrochloride) | 37 | 1 |
| Overview | 37 | 1 |
| Efficacy | 37 | 1 |
| Safety | 37 | 1 |
| Vyvanse (lisdexamfetamine dimesylate) | 38 | 1 |
| Overview | 38 | 1 |
| Efficacy | 38 | 1 |
| Safety | 38 | 1 |
| Kapvay (clonidine hydrochloride) | 39 | 1 |
| Overview | 39 | 1 |
| Efficacy | 39 | 1 |
| Safety | 39 | 1 |
| Focalin XR (dexmethylphenidate hydrochloride) | 40 | 1 |
| Overview | 40 | 1 |
| Efficacy | 40 | 1 |
| Safety | 40 | 1 |
| Generic products | 40 | 1 |
| ADHD Therapeutics Market to 2018 Product Pipeline Analysis | 41 | 7 |
| Introduction | 41 | 1 |
| ADHD Therapeutics Pipeline Pipeline by Phases of Development | 41 | 3 |
| Trends in the ADHD Therapeutic Pipeline | 44 | 4 |
| ADHD Therapeutics Market to 2018 Strategic Consolidations | 48 | 13 |
| Overview | 48 | 1 |
| Deals by Deal Type | 48 | 1 |
| Deals by Year | 49 | 1 |
| Deals by Geography | 49 | 1 |
| Deals by Value | 50 | 1 |
| M&A Landscape | 51 | 1 |
| M&A Deals by Deal Type | 51 | 1 |
| M&A Deals by Year | 52 | 1 |
| M&A Deals by Geography | 53 | 1 |
| M&A Deals by Deal Value | 54 | 1 |
| Sanofi-Aventis Merger, 2004 | 54 | 1 |
| R&D Licensing Agreements | 55 | 1 |
| Deals by Year | 55 | 1 |
| Deals by Geography | 56 | 1 |
| Deals by Deals Value | 57 | 1 |
| Targacept and AstraZeneca Agreement, 2009 | 57 | 1 |
| Co-Development Agreements | 58 | 1 |
| Deals by Year | 58 | 1 |
| Deals by Geography | 59 | 1 |
| Deals by Deal Value | 60 | 1 |
| Shire and New River Co-Development Deal, 2005 | 60 | 1 |
| Appendix | 61 | 6 |
| Abbreviations | 61 | 1 |
| Sources | 61 | 1 |
| Research Methodology | 62 | 4 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 3 |
| Market Size by Geography | 65 | 1 |
| Geographical Landscape | 66 | 1 |
| Pipeline Analysis | 66 | 1 |
| Competitive Landscape | 66 | 1 |
| Expert Panel Validation | 66 | 1 |
| Contact Us | 66 | 1 |
| Disclaimer | 66 | 1 |
